| 发明名称 |
Methods of therapeutic monitoring of phenylacetic acid prodrugs |
| 摘要 |
The present disclosure provides methods for adjusting the dosage of PAA prodrugs (e.g., HPN-100, PBA) based on measurement of PAA and PAGN in plasma and calculating the PAA:PAGN ratio so as to determine whether PAA to PAGN conversion is saturated. |
| 申请公布号 |
US9561197(B2) |
申请公布日期 |
2017.02.07 |
| 申请号 |
US201213610580 |
申请日期 |
2012.09.11 |
| 申请人 |
Horizon Therapeutics, LLC |
发明人 |
Scharschmidt Bruce;Mokhtarani Masoud |
| 分类号 |
A61K31/192;A61K31/216;A61K31/225;G01N33/68 |
主分类号 |
A61K31/192 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. A method of treating a urea cycle disorder in a subject comprising administering to a subject having a plasma PAA to PAGN ratio outside the target range of 1 to 2, a dosage of glyceryl tri-[4-phenylbutyrate] (HPN-100) effective to achieve a plasma PAA to PAGN ratio within the target range of 1 to 2. |
| 地址 |
Lake Forest IL US |
